Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Materialise ( (MTLS) ) just unveiled an announcement.
Materialise NV, a Belgium-based leader in 3D-printed medical devices and additive manufacturing software, serves healthcare, industrial and aerospace clients through its Medical, Software and Manufacturing segments. The company is increasingly emphasizing its high-growth, high-margin Medical business while repositioning Manufacturing away from prototyping toward series production.
On February 19, 2026, Materialise reported its fourth-quarter and full-year 2025 results, showing Q4 revenue up 6.8% to 70.2 million euros and a sharp improvement in profitability driven by 16.3% growth in its Medical segment. For 2025 overall, revenue was broadly flat at 267.6 million euros as strong 15.4% Medical growth offset weakness in Manufacturing, while margins improved, cash reserves rose to 133.9 million euros and the firm strengthened its net cash position, underlining balance-sheet resilience.
Management highlighted the successful Euronext listing and launch of a strategic share buyback in the final quarter of 2025, steps intended to reinforce long-term shareholder value and broaden the company’s capital markets presence. Although net profit for the year fell to 7.7 million euros from 13.4 million euros, the combination of tighter cost control, sustained R&D investment and growing traction in targeted aerospace and defense contracts signals a strategic shift toward higher-value applications that could support future growth.
Segment results underscored this transition, with Medical delivering record quarterly revenues and a 32.0% full-year adjusted EBITDA margin, while Software posted softer sales but improved profitability and Manufacturing saw double-digit revenue declines and negative margins amid weak prototyping demand. Even so, management reported ongoing commercial wins in series manufacturing and maintained operating cash flow generation, suggesting that current pressure in Manufacturing may be cyclical and that the group retains financial flexibility to invest in innovation and market opportunities.
The most recent analyst rating on (MTLS) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Materialise stock, see the MTLS Stock Forecast page.
Spark’s Take on MTLS Stock
According to Spark, TipRanks’ AI Analyst, MTLS is a Neutral.
The score is driven primarily by solid financial quality indicators (strong gross margin, sharply improved free cash flow, and reduced leverage), supported by an above-moving-averages price trend. These positives are tempered by pressured profitability (lower net margin/ROE), mixed momentum signals (slightly negative MACD), expensive valuation (P/E 74.28), and earnings-call risks tied to weakness and losses in the Software/Manufacturing segments despite strong Medical performance and maintained guidance.
To see Spark’s full report on MTLS stock, click here.
More about Materialise
Materialise NV is a Belgium-based leader in 3D-printed medical devices and additive manufacturing software, serving healthcare, industrial and aerospace clients worldwide. The company operates through three main segments—Materialise Medical, Materialise Software and Materialise Manufacturing—with a growing focus on high-margin medical applications and series manufacturing in sectors such as aerospace and defense.
Average Trading Volume: 140,537
Technical Sentiment Signal: Strong Sell
Current Market Cap: $318.4M
Learn more about MTLS stock on TipRanks’ Stock Analysis page.